CED Life Science Conference 2017 - Innovation Room
Sub-sector: Drug Delivery
Year Founded: 2016
Lindy Biosciences is a development-stage company addressing formulation challenges in the rapidly growing biotherapeutics market. Our core technology, Microglassification™, produces spherical, dense, stable particles of a therapeutic protein, ideal for solid injectable formulations such as high-concentration suspensions or encapsulation for controlled release. Over half of all antibody therapeutics are given intravenously, in part because the high dose required cannot be formulated as a solution in a volume small enough for subcutaneous injection. Lindy Biosciences is developing high-dose suspensions of protein that are suitable for subcutaneous injection, decreasing administration costs, increasing patient comfort and compliance, and enabling new high-dose molecules to reach the market.
Dr. Deborah Bitterfield, CEO
KEY MILESTONES TO DATE
- Intellectual property licensed from Duke University (Dr. David Needham)
- Funding: Technology development has been supported by Southeast TechInventures and >$800k in small business innovation research (SBIR) grants from the National Science Foundation and National Institutes of Health
- Secured funding from large pharma for $220k
- Spinning off from Southeast TechInventures
Learn more about the CED Life Science Conference.